Because of this, PD-1 blockade therapies are effective against various types of cancer, such as malignant melanoma, lung cancer, gastric cancer, and head and neck cancer, via reinvigoration of such exhausted T cells in the tumor microenvironment (TME; refs. 2, 3, 9–14). Here, PDCD1 is linked to head and neck cancer.